CMS spokesman Aaron Albright and Theranos both confirmed the proposal was submitted, according to the report. Mr. Albright told Bloomberg CMS staff is currently reviewing the proposal.
CMS released a letter in January that summarized the deficient practices found in a November inspection at Theranos’ Newark, Calif., lab, which included five major infractions for a range of issues including hematology practices, analytic systems and personnel issues. Theranos had 10 days to submit a plan of correction, and it filed for an extension earlier this month.
More articles on leadership and management:
Massachusetts General vs. Johns Hopkins: 6 key comparisons
Why the cancer ‘moonshot’ is not a fitting metaphor
What Justice Scalia’s death could mean for healthcare: 7 things to know
